CannabisNewsBreaks

ThursdayMay 25, 2023 12:58 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be participating in the Tribe Public Webinar, slated for May 31, 2023, and the Investor Summit, scheduled for June 1, 2023. According to the announcement, InMed CEO Eric A. Adams and BayMedica VP of sales and marketing Jerry Griffin will cohost a presentation for the Tribe Public Webinar. The virtual presentation, titled “Addressing the Increasing Demand for Rare Cannabinoids,” will begin at…

Continue Reading

TuesdayMay 23, 2023 3:07 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The findings demonstrate significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” said Dr. Philip Ainslie, cardiovascular advisor to Lexaria and lead investigator of the HYPER-H21-4 study. “The bigger picture is that inflammation is the key basis of atherosclerosis, and…

Continue Reading

ThursdayMay 18, 2023 2:48 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Demonstrates Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced successful completion of its animal study HOR-A22-1, showing significant enhancement in the oral delivery of the estrogen hormone estradiol, an important component of therapeutic products in the women’s health sector. According to the update, the DehydraTECH-estradiol formulation achieved an average peak concentration in the bloodstream (or “Cmax”) of 5.65ng/mL, roughly nine times (900%) higher than that achieved with the control formulation at only 0.63 ng/mL. In addition, with estradiol known to be quickly converted into the metabolite estrone by cells in the uterus, mammary glands and…

Continue Reading

MondayMay 15, 2023 3:33 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (‘CBN’) has completed a phase 2 clinical trial. We look forward to the data read out during 3Q and will then…

Continue Reading

FridayMay 12, 2023 1:13 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced the closing of its public offering of 2,106,000 units, with each consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.95. The warrants are immediately exercisable at a price of $0.95 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants were only purchasable together in the offering but were issued separately and immediately separable upon issuance. Gross proceeds…

Continue Reading

ThursdayMay 11, 2023 2:54 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced completion of batch manufacturing of the DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for its upcoming U.S. phase 1b hypertension clinical trial HYPER-H23-1. According to the update, Lexaria retained the services of a U.S. contract manufacturing organization to produce the materials compliant with current Good Manufacturing Practice (“cGMP”) regulations as mandated by the Food and Drug Administration (“FDA”). Filling into capsules is expected to be completed this month. This will follow with analytical release and stability testing in order to gather essential quality control data necessary for…

Continue Reading

WednesdayMay 10, 2023 2:20 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the results of the 2023 Annual Meeting. According to the update, the company held the meeting at 1:00 p.m. PT on May 9, 2023, whereby there were 3,372,024 shares of the company represented in person or by proxy, constituting 56.3% of the company's issued share capital as of the meeting date of March 13, 2023. The matters voted upon and the final voting results are set forth as detailed in the announcement. All proposals are described in detail in Lexaria’s proxy statement filed with the Securities…

Continue Reading

MondayMay 08, 2023 3:04 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the announcement, the study is the result of the focus Lexaria has had for years on oral nicotine formulations as an alternative to vaping or smoking; the company noted that results from the study could lead to more rapid commercial adoption and distribution of its patented DehydraTECH(TM) absorption technology, which is designed to improve oral uptake. Statistics show that some 7 million people die every year from cigarette smoking, and alternatives for nicotine delivery…

Continue Reading

MondayApr 24, 2023 1:29 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards CRO Contract for Upcoming Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it awarded the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. for its expected upcoming Food and Drug Administration (“FDA”)-registered, U.S. phase 1b Investigational New Drug (“IND”) hypertension study HYPER-H23-1 with its patented DehydraTECH-powered cannabidiol (“DehydraTECH-CBD”). According to the announcement, HYPER-H23-1 is entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension.” The study’s primary objective will be to evaluate safety and tolerability in 120 hypertensive patients,…

Continue Reading

ThursdayApr 20, 2023 10:48 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In Japan, the company secured a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria’s fifth awarded patent in Japan, providing strength to its growing Japanese patent portfolio. In Australia, Lexaria has received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria’s 10th patent in Australia and its second in this patent family.…

Continue Reading